ArticlePharmaceutical biology2026
Aqueous extract of
Article in Pharmaceutical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAtopic dermatitis is a chronic inflammatory skin disorder characterized by epidermal barrier dysfunction and dysregulated type 2 helper T cell (Th2)-mediated immune responses.
objectiveThis study evaluated the protective effects of MATERIALS AND
methodsAtopic dermatitis-like lesions were induced in 5-week-old female BALB/c mice by repeated epicutaneous ovalbumin (OVA) sensitization, and EA was orally administered for six weeks. Epidermal barrier function, histopathology, immunoglobulins, cytokines, and mitogen-activated protein kinase (MAPK) signaling were evaluated. Pyromeconic acid (PA), a representative constituent of EA, was examined in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.
resultsEA attenuated dermatitis-like lesions and reduced dermatitis scores in OVA-sensitized mice. EA decreased transepidermal water loss, increased skin hydration, restored filaggrin expression, and reduced epidermal and dermal thickening, mast cell infiltration, CD4 DISCUSSION AND
conclusionEA attenuated OVA-induced atopic dermatitis-like inflammation in association with improved epidermal barrier function, reduced Th2-associated immune responses, and attenuated MAPK signaling. PA showed anti-inflammatory activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.